Bristol-Myers
Squibb Company (NYSE:BMY) and Samsung
BioLogics today announced the companies will increase the scope of
their existing manufacturing agreement in which Samsung will manufacture
commercial drug substances and drug product for several Bristol-Myers
Squibb biologic medicines at its Incheon manufacturing site. Financial
terms of the agreement are not disclosed.
Bristol-Myers Squibb and Samsung announced their first manufacturing
agreement in July 2013 to collaborate in the production of a single
commercial antibody cancer drug substance.
"Biologic medicines that treat serious diseases are an integral part of
Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline,” said Lou
Schmukler, president, Global Manufacturing & Supply. “The expanded
relationship with Samsung will increase our biologics manufacturing
capability and give us the flexibility to respond to increased demand in
order to meet the global needs of patients."
"Samsung is delighted to reach the second manufacturing agreement with
Bristol-Myers Squibb and we look forward to delivering top quality GMP
production," said Dr. TH Kim, president and CEO of Samsung BioLogics.
“It represents another significant step for Samsung and Bristol-Myers
Squibb in strengthening our biopharmaceutical manufacturing
relationship.”
Samsung brings global biopharmaceutical capability through its
fully-integrated production facilities that offer process development,
drug substance manufacturing, and drug product fill & finish services at
one location. In addition to its current biologics manufacturing
facility in Incheon, Korea, the company is currently building a second
facility, also in Incheon, which is expected to be completed in early
2015.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
About Samsung BioLogics
Samsung BioLogics is a global full-service provider of quality-driven
contract process development and cGMP manufacturing to the global
biopharmaceutical industry. Our facilities are custom designed for
monoclonal & recombinant production with maximum flexibility. Our
one-stop services include cell line generation, process and analytical
method development, analytical services, clinical and commercial bulk
cGMP manufacturing of drug substance and drug product including quality
assurance, quality control, regulatory compliance standards & support
for our customers. For additional information about the company, please
visit http://www.samsungbiologics.com.
Samsung Disclaimer
This press release may contain certain forward-looking statements that
reflect our current views and expectations with respect to our
performance, businesses, and future events. Please understand that these
statements are subject to a number of risks, uncertainties, and
assumptions, any of which could cause actual results to materially
differ from the plans, objectives, expectations, estimates, and
intentions we express. In no event will we or any of our subsidiaries,
affiliates, directors, officers, agents, or employees be liable before
any third party, including investors, for any investment or business
decision made or action taken based on information and statements
contained in this press release or for any consequential, special, or
similar damages.
Copyright Business Wire 2014